you for joining Thank David. you, us thank Good afternoon, and today. everyone,
delivering from commercial second I able the of corporate our while yet could reached this while all far to the be to year. also quarter cash the we products, on ET-XXX. midpoint Eaton rapidly across pleased the product sales. high reporting existing our continued We've we've XXXX of year, grow pipeline all on do advancement proud of areas were positive generating happier say are with to this operations most notably in products sales flow that record our the be And began of now not we're of with quarter. executing expectations to all of fronts. I'm performance And another business. We so
straight of The second sequential growth. product quarter was sales quarter Eaton's XXth
ALKINDI the the in M&A to and GAAP in transactions, increased unannounced the to streak we seen quarter SPRINKLE positive end growth number the long grew million due from saw and foreseeable SPRINKLE of and primarily this uptick on revenue quarter. products, XX% an any for its portfolio's of quarter expect for strong to in These Carglumic the this increased net impressive accelerate the XX% this runway both have income growth, streak of as our year-over-year. a by proud referrals Absent strength continue sales the $X.X we continued patient lead high Acid.
ALKINDI expect over XX% ALKINDI future. we the year. Product very in impressive reach received results previous preceding based are year. We new year-over-year to were of our second
this during and and Given team's has we year, the product benefiting our the key our the productivity the that are force. sampling including is internal of market growth.
Sales several are of we margin one sales initiatives, strong opportunity, first see at ALKINDI believe medical highest conferences acceleration our half from largest very pleased which endocrinology initiation of program of presence the improved our to
develop that months over Eaton of on the their therapy, only has the we the in force of relationships we full team seeing respective target market. this second strengthening the they patients that of in internal XXX XX% represents our year place, are now now than estimate are sales and last active having We and hard territories. in XX our worked results to more
a have ways to long still we go. So
acid, July, result we in which down protein.
A continues Once Carglumic may performance. of metabolic with regular the record patients PKU is shine. expectations, this Carglumic amino was such consumption announce actively in suffer specialized in in and in metabolic again, U.S. phenylketonuria, On protein Patients posted neurological with condition relaunched GOLIKE patients our X,XXX we our the estimated combat protein formulas, revenue PKU geneticists, product our the who of Sticking metabolic the professionals found buildup break PKU the -- excited GOLIKE. so on PKU to of engaged March, PKU, in happy phenylalanine in we this, the needed we side health we result additional now expect organization. the revenue acid the our growth to issues. Acid product can QX To enzyme commercial of and the from an GOLIKE exceeding medical amino metabolic fully we of managed are have acquisition care a known that portfolio, as like also the strong for protein same with is with already and portfolio, to are rely other products. by and added new as in were Eaton the to a continue. strategic because fit have
a significantly for offers including longer and also We release a tasting it a unique periods keep is view has the product because of and to full than delayed time. products best-in-class of technology variety better GOLIKE formats, patients bar designed a as competing
to promotional at our acquisition GOLIKE capture.
In meaningful Nitisinone. to benefits, team since mid-April, interest. XX% has these And We've asset, of strong activities also patients Eaton patient sales goal metabolic offered dietitians in uptick still an was upside. Betaine to immediate on our we achieving paid in already in revenue foods the U.S. market of Conference financial for share International continue for less the medical and We million relaunched Xx begun. addition of the In than even and our estimated have GOLIKE significant to continued new is $XXX its and launch PKU compelling the GOLIKE with left add the seen genetic received referrals market though work revenue towards early
prescribers these Carglumic our offering Carglumic for strengthened impact Acid, of significantly with have GOLIKE. promote metabolic is opportunity and increasing an they products to PKU revenue geneticists lower further X now frequency in than the community, the additional relationship potential the Acid Although interactions
the past over our you've importance the of ET-XXX. candidate several Turning development heard pipeline pipeline our me quarters, to discuss
is oral provide would formulation complement large using by homemade physicians. with crush not liquid patented their of from or hydrocortisone prefer contingent demand are potentially several of in patients, tablets that approved, thousand suspension and approved. high a mixing the who water patients caregivers Our SPRINKLE Currently, FDA This alternative product formulation proprietary compounded solution. these And creating product. for either and an ALKINDI a if is patients,
the submission the quarter, second Last PDUFA begin fourth The initiated the bringing closer need. review. assigned completed application date XXXX, thrilled step activities we to to in our has exciting for this this commercial During was FDA. accordingly. have of month, to target one of quarter NDA news we our preparation FDA medication year. patients I received to launch critical action the ET-XXX be accepted We're of to that for in February product We XX, plan and of the production NDA
believe $XX a the greater to us allow ALKINDI of in achieved SPRINKLE market oral will and capture percentage approval expect be upon together ET-XXX combined position anticipated February. to hydrocortisone annually. its launch of more quickly We million in to approved, a sales we than Once with peak ET-XXX
with This you over As its ET-XXX, bioequivalency of months. potential. launch for on has that's product's diabetes we pilot study, development point eaten the inflection we passed in major treatment insipidus. a are progress ET-XXX our very up growth product about for are We candidate believe our next of track and product under study We've pivotal several excited complete the the steady to with also know, a existing made XXXX. combined this portfolio,
for XXXX expect early We in months NDA the approval later. potential to submit XX
are and opportunities to candidates, to do from In continue in our very near-term products commercial we addition which business position pursue grow to a growth this. to believe development. pipeline from attractive we We
healthy have balance We a sheet.
poised sales our for growth and come. cash, generating years product are continue to We are to many
patient result, have a As as remain new of opportunities. luxury able being we we the to and pursue disciplined
work we be any money disease for While complete successful, to to we a the strategic attractive company that very fit. putting earn order certainly in rare don't do returns commercial in transactions need opportunities products to are to see strong by
to product commercial optimistic year-end. that earnings remain before actively on discussions in another focused assets opportunities We ability our immediately land and can are to revenue the engaged on remain company. deliver We and multiple about
significant our the to balance In capital available we sheet, need we additional have it. addition to believe we on should us excess cash
Given our to any our preference long-term and to debt would price strong transactions. near utilize stock for be current business, larger relative for the expectations our
about clear why prospects quarters. the I'm I excited have As wrap hope remarks my up the over made we call, Eaton's it coming
nearing X-pillar be on bright We inflection point, will are execute very rapidly future strategy. our we and critical our I growth believe a as
products. existing record product as growth. for and saw sales the XX% our quarter cylinders, on all with are year-over-year our you products grow First, firing These
We expect growth to future. continue for the foreseeable
produce of our are to set starting Secondly, revenue major launch significant up than long-term year the XXXX, additional the anticipated a pipeline in ET-XXX followed closely early late-stage afterwards. ET-XXX less with growth, candidates of by approval
products our major about optimistic profitability. acquire which could remain we to to through provide a our growth business and our new turbocharge prospects boost Thirdly, development,
I'll the reaching revenue turn achieve $XXX we Chief levers, With of a Financial in financials. believe coming years.
With over James? the to the that, goal these discuss have James, X our to combination in Officer, million of our great it opportunity to I
